Macula Retina and Vitreous

A Safety and Tolerability Trial of CNTF in Patients with MacTel Type 2

This study is assessing the safety of the NT-501 implant in patients with macular telangiectasia type 2. The device, an implant, is a small capsule of cells that is placed inside the eye. This allows a controlled, sustained release of CNTF directly to the retina.

Investigators: Jean-Pierre Hubschman, MD, Allan E. Kreiger, MD, and Steven D. Schwartz, MD

A Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

This study is a Phase III, open label, multicenter, randomized, evaluating the efficacy and safety of lampalizumab in patients with geographic atrophy of the retina resulting from age-related macular degeneration.

Investigators: David Sarraf, MD, Steven D. Schwartz, MD, Michael Gorin, MD PhD, Jean-Pierre Hubschman, MD, Allan E. Kreiger, MD, Colin McCannel, MD, Pradeep Prasad, MD, and Irena Tsui, MD

Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eye at High Risk

This study will evaluate the safety and efficacy of an intravitreous anti-vascular endothelial growth factor (anti-VGEF) regimen for prevention of PDR or DME or both in eyes that are at high risk for worsening to PDR or DME.

Investigators: Colin McCannel, MD, Michael Gorin, MD PhD, Michael Ip, MD and David Sarraf MD

Study of the Efficacy, Safety, and Tolerability of Repeated Doses of an Intravitreal drug in Patients with Neovascular Age-Related Macular Degeneration

This Phase 2, year long study will require the recruitment of patients with wet or neovascular age related macular degeneration who are naive to anti-VEGF treatment.The subjects will receive intravitreal injections every 4 weeks of their assigned treatment tier for 3 treatments.

Investigators: Srinivas Sadda, MD, David Sarraf, MD, Gad Heilweil, MD, Colin McCannel, MD, Michael Gorin, MD PhD

Study to evaluate the use of an implant for patients with macular degeneration

A clinical trial to determine the efficacy, safety, and pharmacokinetics of ranibizumab delivered through the Implant using three ranibizumab formulation arms compared with the control arm in patients with subfoveal neovascular (wet) age-related macular degeneration (AMD). The study will also evaluate the safety of the RPDS combination product. The study will include screening and randomization visits followed by a treatment period.

Investigators: Michael Gorin MD PhD, Colin McCannel, MD, Tara McCannel MD PhD, Pradeep Prasad MD, and David Sarraf MD

Clinical Trial of a new drug for Stargardt’s disease

The purpose of this research study is to find out whether a new drug for Stargardt disease is safe and effective.  There are currently no proven treatments for Stargardt’s disease, a disease that leads to blindness in almost all cases. 

Investigators: Michael Gorin MD PhD and Steve Nusinowitz PhD